The agreement will allow Tate& Lyle to add Lipid Nutrition's PinnoThin, Clarinol and Marinol to its Enrich portfolio, which exists to help food and beverage makers add extra nutrients to products without losing taste. Although the potential value of the deal has not been disclosed, the partnership will be a massive boost to both companies and for the award-winning ingredient PinnoThin. The first product prototype can be seen at Food Ingredients Europe next week in a tomato soup containing PinnoThin - containing pinolenic acid derived from the seeds of the Korean pine nut tree (Pinus koraiensis) - which is aimed at increasing satiety. James Blunt, Tate & Lyle product management director, told NutraIngredients.com that a soup was a perfect product for PinnoThin, as it was already seen as a healthy food. "It is aimed at people who don't have a long time to eat but want to feel full. "We have done some consumer research in France and UK and taste always come as being the number one area of importance - people like eating." Enrich focuses on three main themes - digestive health and immunity, obesity and weight management, and children's health. The other two Lipid Nutrition ingredients Tate & Lyle will be using are Clarinol and Marinol. Clarinol contains conjugated linoleic acid (CLA) and is aimed at reducing body fat. Marinol consists of omega-3 and is aimed at boosting heart and brain health. In April Lipid Nutrition was awarded most innovative ingredient at the First International Conference on Innovations and Trends in Weight Loss and Weight Management for PinnoThin. As part of the deal, Tate & Lyle will have exclusive rights to market the three ingredients in Europe, the Middle East and Africa. With 50 per cent of Europeans and 62 per cent of Americans classed as overweight, the food industry is waking up to the potential of products for weight loss and management, with the category already estimated to already be worth $7bn worldwide. Just last week a shocking report predicted more than half of the people in Britain would be obese by 2050, and the cost, in terms of health care provision and lost working hours, could reach £45bn a year. Blunt said: "Our R&D teams have already started to develop a range of Enrich prototypes with these ingredients. This means more choice for our customers and enables them to develop consumer products with a health proposition targeted to specific market segments." The agreement came about after Tate & Lyle announced it would establish a Wellness and Nutrition centre in Lille, France. The €4m centre will include laboratories and pilot plant facilities for customers. It will focus on developing new ingredients in the field of wellness and nutrition, catering for beverage, dairy, bakery, and convenience food. The establishment of the centre underlines Tate & Lyle's focus on the development of value-added ingredients.